CytomX Therapeutics Inc (CTMX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.71+0.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CTMX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 214.4% |
| Our one-year growth estimate | diamond | 46.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 167.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CTMX — director transition
Dated 2026-07-27
Director — Charles Fuchs, M.D., M.P.H.: Dr. Charles Fuchs was appointed to the Board of Directors as a Class II director.
Why it matters: This data will help choose doses for the colorectal cancer study. Good results could help the drug's development.
Supportive ifA press release said Phase 1 data for Varseta-M is good. This is for advanced colorectal cancer.
Worry ifNo data update or negative results from the Phase 1 study.
Why it matters: New groups may show confidence in Varseta-M's use beyond colorectal cancer.
Supportive ifA press release confirms new Phase 1 groups for Varseta-M in non-CRC.
Worry ifNo announcement of new cohorts by the end of 2026.
Why it matters: This data will show how well CX-801 works in advanced melanoma. Good results could support the PROBODY platform.
Supportive ifA press release said initial clinical data for CX-801 with KEYTRUDA is good.
Worry ifThere are bad results or delays in reporting initial clinical data for CX-801.
Why it matters: Strong revenue growth shows the company is focused on making more money.
Supportive ifQuarterly revenue growth exceeds 10% year over year.
Worry ifQuarterly revenue growth falls below 5% year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$217 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $638 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,689 loss on $10,000 · 56.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Starting this study could help Varseta-M in colorectal cancer. Delays could slow growth.
Supportive ifA press release confirms the start of the Phase 1/2 chemotherapy study in Q4 2026.
Worry ifAn announcement that the study start is delayed or canceled.
Why it matters: New developments could improve CytomX's pipeline and show its strategy is working. No news may mean problems.
Supportive ifA press release shares new goals in the Regeneron partnership.
Worry ifSilence or bad news about the collaboration or its progress.